The results further showed a positive association between sPD-L1 and adverse clinical outcome, especially sPD-L1 in serum, and it appears the urine levels of sPD-L1 are higher in RCC patients presenting with metastatic disease at diagnosis. The gene discussed is SPDL1; the disease is renal cell carcinoma.